nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.0954	0.128	CbGbCtD
Gefitinib—CYP3A5—Sulfasalazine—ankylosing spondylitis	0.0528	0.071	CbGbCtD
Gefitinib—ALB—Prednisone—ankylosing spondylitis	0.0526	0.0706	CbGbCtD
Gefitinib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0476	0.0639	CbGbCtD
Gefitinib—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0454	0.0609	CbGbCtD
Gefitinib—CYP1A1—Dexamethasone—ankylosing spondylitis	0.0439	0.059	CbGbCtD
Gefitinib—ABCG2—Methotrexate—ankylosing spondylitis	0.0382	0.0514	CbGbCtD
Gefitinib—CYP2C19—Prednisone—ankylosing spondylitis	0.0341	0.0458	CbGbCtD
Gefitinib—ABCB1—Betamethasone—ankylosing spondylitis	0.0295	0.0396	CbGbCtD
Gefitinib—ABCB1—Prednisolone—ankylosing spondylitis	0.0291	0.0391	CbGbCtD
Gefitinib—ABCB1—Prednisone—ankylosing spondylitis	0.0275	0.0369	CbGbCtD
Gefitinib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0272	0.0365	CbGbCtD
Gefitinib—CYP3A5—Dexamethasone—ankylosing spondylitis	0.0264	0.0354	CbGbCtD
Gefitinib—ALB—Methotrexate—ankylosing spondylitis	0.0264	0.0354	CbGbCtD
Gefitinib—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0213	0.0286	CbGbCtD
Gefitinib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0206	0.0277	CbGbCtD
Gefitinib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0177	0.0238	CbGbCtD
Gefitinib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0177	0.0237	CbGbCtD
Gefitinib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0174	0.0234	CbGbCtD
Gefitinib—ABCB1—Dexamethasone—ankylosing spondylitis	0.0172	0.023	CbGbCtD
Gefitinib—CYP3A4—Prednisone—ankylosing spondylitis	0.0165	0.0221	CbGbCtD
Gefitinib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0162	0.0217	CbGbCtD
Gefitinib—ABCB1—Methotrexate—ankylosing spondylitis	0.0138	0.0185	CbGbCtD
Gefitinib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0103	0.0138	CbGbCtD
Gefitinib—IRAK4—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.00502	0.0463	CbGpPWpGaD
Gefitinib—MKNK2—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.00501	0.0461	CbGpPWpGaD
Gefitinib—IRAK4—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.00441	0.0407	CbGpPWpGaD
Gefitinib—IRAK1—IL1-mediated signaling events—IL1R2—ankylosing spondylitis	0.00333	0.0307	CbGpPWpGaD
Gefitinib—IRAK1—NOD1/2 Signaling Pathway—CARD9—ankylosing spondylitis	0.00311	0.0287	CbGpPWpGaD
Gefitinib—IRAK1—Interleukin-1 signaling—IL1R2—ankylosing spondylitis	0.00293	0.027	CbGpPWpGaD
Gefitinib—IRAK4—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.00238	0.0219	CbGpPWpGaD
Gefitinib—EGFR—EGFR Transactivation by Gastrin—MMP3—ankylosing spondylitis	0.00232	0.0214	CbGpPWpGaD
Gefitinib—IRAK1—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—CARD9—ankylosing spondylitis	0.00212	0.0196	CbGpPWpGaD
Gefitinib—IRAK4—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.00209	0.0192	CbGpPWpGaD
Gefitinib—IRAK4—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00199	0.0184	CbGpPWpGaD
Gefitinib—MKNK1—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00188	0.0174	CbGpPWpGaD
Gefitinib—IRAK4—Endogenous TLR signaling—TLR4—ankylosing spondylitis	0.00181	0.0167	CbGpPWpGaD
Gefitinib—MKNK1—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.00178	0.0164	CbGpPWpGaD
Gefitinib—IRAK4—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.00171	0.0158	CbGpPWpGaD
Gefitinib—IRAK1—IL1-mediated signaling events—IL1RN—ankylosing spondylitis	0.00158	0.0145	CbGpPWpGaD
Gefitinib—IRAK1—Apoptosis Modulation and Signaling—IL1R2—ankylosing spondylitis	0.00152	0.014	CbGpPWpGaD
Gefitinib—IRAK4—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.0015	0.0138	CbGpPWpGaD
Gefitinib—IRAK1—Interleukin-1 signaling—IL1RN—ankylosing spondylitis	0.00138	0.0128	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—IL1R2—ankylosing spondylitis	0.00132	0.0122	CbGpPWpGaD
Gefitinib—IRAK4—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.00132	0.0122	CbGpPWpGaD
Gefitinib—IRAK1—Endogenous TLR signaling—TLR4—ankylosing spondylitis	0.0012	0.0111	CbGpPWpGaD
Gefitinib—IRAK4—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.00116	0.0107	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.00116	0.0107	CbGpPWpGaD
Gefitinib—IRAK1—IL1-mediated signaling events—IL1A—ankylosing spondylitis	0.00114	0.0105	CbGpPWpGaD
Gefitinib—ERBB3—a6b1 and a6b4 Integrin signaling—IL1A—ankylosing spondylitis	0.00109	0.01	CbGpPWpGaD
Gefitinib—IRAK1—Interleukin-1 signaling—IL1A—ankylosing spondylitis	0.000997	0.00919	CbGpPWpGaD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000966	0.0089	CbGpPWpGaD
Gefitinib—IRAK4—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000942	0.00869	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.00093	0.00857	CbGpPWpGaD
Gefitinib—CSNK1E—Danazol—Prednisone—ankylosing spondylitis	0.000895	0.123	CbGdCrCtD
Gefitinib—IRAK1—Structural Pathway of Interleukin 1 (IL-1)—IL1A—ankylosing spondylitis	0.000876	0.00808	CbGpPWpGaD
Gefitinib—IRAK1—Apoptosis Modulation and Signaling—TNFRSF1B—ankylosing spondylitis	0.000848	0.00781	CbGpPWpGaD
Gefitinib—Pleural effusion—Methotrexate—ankylosing spondylitis	0.000841	0.00602	CcSEcCtD
Gefitinib—Thrombophlebitis—Triamcinolone—ankylosing spondylitis	0.000818	0.00586	CcSEcCtD
Gefitinib—Dry eye—Betamethasone—ankylosing spondylitis	0.000817	0.00585	CcSEcCtD
Gefitinib—Dry eye—Dexamethasone—ankylosing spondylitis	0.000817	0.00585	CcSEcCtD
Gefitinib—Thrombophlebitis—Methylprednisolone—ankylosing spondylitis	0.000816	0.00584	CcSEcCtD
Gefitinib—Ulcer—Prednisone—ankylosing spondylitis	0.000815	0.00583	CcSEcCtD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.00081	0.00747	CbGpPWpGaD
Gefitinib—Dermatitis bullous—Prednisolone—ankylosing spondylitis	0.000806	0.00577	CcSEcCtD
Gefitinib—IRAK1—IL-1 signaling pathway—IL1A—ankylosing spondylitis	0.000773	0.00712	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.000754	0.00695	CbGpPWpGaD
Gefitinib—Thrombophlebitis—Dexamethasone—ankylosing spondylitis	0.000742	0.00531	CcSEcCtD
Gefitinib—Thrombophlebitis—Betamethasone—ankylosing spondylitis	0.000742	0.00531	CcSEcCtD
Gefitinib—Dermatitis bullous—Triamcinolone—ankylosing spondylitis	0.000741	0.0053	CcSEcCtD
Gefitinib—Proteinuria—Methotrexate—ankylosing spondylitis	0.000733	0.00525	CcSEcCtD
Gefitinib—Protein urine present—Methotrexate—ankylosing spondylitis	0.000723	0.00518	CcSEcCtD
Gefitinib—Eye pain—Betamethasone—ankylosing spondylitis	0.000712	0.00509	CcSEcCtD
Gefitinib—Eye pain—Dexamethasone—ankylosing spondylitis	0.000712	0.00509	CcSEcCtD
Gefitinib—Dry skin—Prednisolone—ankylosing spondylitis	0.000706	0.00505	CcSEcCtD
Gefitinib—IRAK1—p75(NTR)-mediated signaling—MMP3—ankylosing spondylitis	0.000681	0.00628	CbGpPWpGaD
Gefitinib—Ulcer—Methotrexate—ankylosing spondylitis	0.000681	0.00488	CcSEcCtD
Gefitinib—IRAK4—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.000678	0.00625	CbGpPWpGaD
Gefitinib—EGFR—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP3—ankylosing spondylitis	0.000678	0.00625	CbGpPWpGaD
Gefitinib—Dermatitis bullous—Betamethasone—ankylosing spondylitis	0.000672	0.00481	CcSEcCtD
Gefitinib—Dermatitis bullous—Dexamethasone—ankylosing spondylitis	0.000672	0.00481	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000659	0.00607	CbGpPWpGaD
Gefitinib—Respiratory failure—Methotrexate—ankylosing spondylitis	0.000656	0.0047	CcSEcCtD
Gefitinib—Pancreatitis—Prednisolone—ankylosing spondylitis	0.000652	0.00467	CcSEcCtD
Gefitinib—Thrombophlebitis—Prednisone—ankylosing spondylitis	0.000646	0.00463	CcSEcCtD
Gefitinib—MKNK1—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000641	0.00591	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—IL12B—ankylosing spondylitis	0.000641	0.00591	CbGpPWpGaD
Gefitinib—Cystitis noninfective—Methotrexate—ankylosing spondylitis	0.000629	0.0045	CcSEcCtD
Gefitinib—Melaena—Methotrexate—ankylosing spondylitis	0.000629	0.0045	CcSEcCtD
Gefitinib—CSNK1E—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000626	0.0858	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000626	0.0858	CbGdCrCtD
Gefitinib—IRAK1—Signaling by Interleukins—IL1RN—ankylosing spondylitis	0.000626	0.00577	CbGpPWpGaD
Gefitinib—Alanine aminotransferase increased—Methylprednisolone—ankylosing spondylitis	0.000623	0.00446	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—ankylosing spondylitis	0.000622	0.00445	CcSEcCtD
Gefitinib—EGFR—MAPK Signaling Pathway—IL1R2—ankylosing spondylitis	0.000621	0.00572	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL1R2—ankylosing spondylitis	0.000617	0.00569	CbGpPWpGaD
Gefitinib—CSNK1E—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000616	0.0844	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000616	0.0844	CbGdCrCtD
Gefitinib—EGFR—Posttranslational regulation of adherens junction stability and dissassembly—MMP3—ankylosing spondylitis	0.000609	0.00561	CbGpPWpGaD
Gefitinib—IRAK4—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000608	0.0056	CbGpPWpGaD
Gefitinib—EGFR—a6b1 and a6b4 Integrin signaling—IL1A—ankylosing spondylitis	0.000607	0.00559	CbGpPWpGaD
Gefitinib—CSNK1E—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000602	0.0825	CbGdCrCtD
Gefitinib—CSNK1E—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000602	0.0825	CbGdCrCtD
Gefitinib—Pancreatitis—Triamcinolone—ankylosing spondylitis	0.0006	0.0043	CcSEcCtD
Gefitinib—Pancreatitis—Methylprednisolone—ankylosing spondylitis	0.000599	0.00429	CcSEcCtD
Gefitinib—Dry skin—Betamethasone—ankylosing spondylitis	0.000589	0.00422	CcSEcCtD
Gefitinib—Dry skin—Dexamethasone—ankylosing spondylitis	0.000589	0.00422	CcSEcCtD
Gefitinib—IRAK1—EBV LMP1 signaling—TNF—ankylosing spondylitis	0.000587	0.00541	CbGpPWpGaD
Gefitinib—Hypokalaemia—Dexamethasone—ankylosing spondylitis	0.000585	0.00419	CcSEcCtD
Gefitinib—Hypokalaemia—Betamethasone—ankylosing spondylitis	0.000585	0.00419	CcSEcCtD
Gefitinib—ERBB3—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000583	0.00537	CbGpPWpGaD
Gefitinib—Bladder pain—Methotrexate—ankylosing spondylitis	0.000582	0.00417	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—ankylosing spondylitis	0.000582	0.00417	CcSEcCtD
Gefitinib—Conjunctivitis—Prednisolone—ankylosing spondylitis	0.000577	0.00413	CcSEcCtD
Gefitinib—CSNK1E—Betamethasone—Prednisone—ankylosing spondylitis	0.000572	0.0783	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisone—ankylosing spondylitis	0.000572	0.0783	CbGdCrCtD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000569	0.00525	CbGpPWpGaD
Gefitinib—CSNK1E—Betamethasone—Prednisolone—ankylosing spondylitis	0.000558	0.0764	CbGdCrCtD
Gefitinib—CSNK1E—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000558	0.0764	CbGdCrCtD
Gefitinib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000544	0.0039	CcSEcCtD
Gefitinib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000544	0.0039	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—ankylosing spondylitis	0.00054	0.00387	CcSEcCtD
Gefitinib—Haemoglobin—Prednisolone—ankylosing spondylitis	0.000535	0.00383	CcSEcCtD
Gefitinib—Haemorrhage—Prednisolone—ankylosing spondylitis	0.000533	0.00381	CcSEcCtD
Gefitinib—Conjunctivitis—Triamcinolone—ankylosing spondylitis	0.00053	0.0038	CcSEcCtD
Gefitinib—IRAK4—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000524	0.00483	CbGpPWpGaD
Gefitinib—Hepatic failure—Methotrexate—ankylosing spondylitis	0.00052	0.00372	CcSEcCtD
Gefitinib—Epistaxis—Triamcinolone—ankylosing spondylitis	0.000515	0.00368	CcSEcCtD
Gefitinib—Dry skin—Prednisone—ankylosing spondylitis	0.000513	0.00367	CcSEcCtD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000512	0.00472	CbGpPWpGaD
Gefitinib—Hypokalaemia—Prednisone—ankylosing spondylitis	0.000509	0.00365	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000506	0.00467	CbGpPWpGaD
Gefitinib—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000502	0.0036	CcSEcCtD
Gefitinib—Weight decreased—Betamethasone—ankylosing spondylitis	0.000502	0.0036	CcSEcCtD
Gefitinib—IRAK4—Immune System—KIR3DL1—ankylosing spondylitis	0.000501	0.00462	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—IL12B—ankylosing spondylitis	0.0005	0.00461	CbGpPWpGaD
Gefitinib—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.000496	0.00355	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Prednisone—ankylosing spondylitis	0.000493	0.00353	CcSEcCtD
Gefitinib—IRAK4—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000493	0.00455	CbGpPWpGaD
Gefitinib—Haemoglobin—Triamcinolone—ankylosing spondylitis	0.000492	0.00352	CcSEcCtD
Gefitinib—Haemoglobin—Methylprednisolone—ankylosing spondylitis	0.000491	0.00352	CcSEcCtD
Gefitinib—Haemorrhage—Triamcinolone—ankylosing spondylitis	0.00049	0.00351	CcSEcCtD
Gefitinib—Haemorrhage—Methylprednisolone—ankylosing spondylitis	0.000489	0.0035	CcSEcCtD
Gefitinib—Conjunctivitis—Dexamethasone—ankylosing spondylitis	0.000481	0.00345	CcSEcCtD
Gefitinib—Conjunctivitis—Betamethasone—ankylosing spondylitis	0.000481	0.00345	CcSEcCtD
Gefitinib—Arrhythmia—Prednisolone—ankylosing spondylitis	0.000476	0.00341	CcSEcCtD
Gefitinib—Pancreatitis—Prednisone—ankylosing spondylitis	0.000474	0.00339	CcSEcCtD
Gefitinib—MKNK1—Disease—ANTXR2—ankylosing spondylitis	0.000472	0.00435	CbGpPWpGaD
Gefitinib—CHEK2—Danazol—Prednisone—ankylosing spondylitis	0.000458	0.0628	CbGdCrCtD
Gefitinib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000457	0.00327	CcSEcCtD
Gefitinib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000454	0.00325	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—CARD9—ankylosing spondylitis	0.000452	0.00417	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by Interleukins—IL1A—ankylosing spondylitis	0.00045	0.00415	CbGpPWpGaD
Gefitinib—Haemoglobin—Betamethasone—ankylosing spondylitis	0.000447	0.0032	CcSEcCtD
Gefitinib—Haemoglobin—Dexamethasone—ankylosing spondylitis	0.000447	0.0032	CcSEcCtD
Gefitinib—Haemorrhage—Betamethasone—ankylosing spondylitis	0.000444	0.00318	CcSEcCtD
Gefitinib—Haemorrhage—Dexamethasone—ankylosing spondylitis	0.000444	0.00318	CcSEcCtD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000444	0.0041	CbGpPWpGaD
Gefitinib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000443	0.00317	CcSEcCtD
Gefitinib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.00044	0.00315	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.00044	0.00405	CbGpPWpGaD
Gefitinib—IRAK4—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000439	0.00405	CbGpPWpGaD
Gefitinib—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.000438	0.00313	CcSEcCtD
Gefitinib—Weight decreased—Prednisone—ankylosing spondylitis	0.000438	0.00313	CcSEcCtD
Gefitinib—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000437	0.00313	CcSEcCtD
Gefitinib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000425	0.00305	CcSEcCtD
Gefitinib—Angioedema—Prednisolone—ankylosing spondylitis	0.000424	0.00303	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.000421	0.00301	CcSEcCtD
Gefitinib—Malaise—Prednisolone—ankylosing spondylitis	0.000418	0.00299	CcSEcCtD
Gefitinib—Eye disorder—Betamethasone—ankylosing spondylitis	0.000415	0.00297	CcSEcCtD
Gefitinib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.000415	0.00297	CcSEcCtD
Gefitinib—ERBB3—B Cell Activation—CD79A—ankylosing spondylitis	0.000411	0.00379	CbGpPWpGaD
Gefitinib—IRAK1—MyD88:Mal cascade initiated on plasma membrane—TLR4—ankylosing spondylitis	0.000403	0.00372	CbGpPWpGaD
Gefitinib—Angiopathy—Betamethasone—ankylosing spondylitis	0.000403	0.00289	CcSEcCtD
Gefitinib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000403	0.00289	CcSEcCtD
Gefitinib—ERBB3—Immune System—KIR3DL1—ankylosing spondylitis	0.0004	0.00368	CbGpPWpGaD
Gefitinib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000397	0.00284	CcSEcCtD
Gefitinib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000397	0.00284	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000396	0.00284	CcSEcCtD
Gefitinib—MAP2K5—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000394	0.00363	CbGpPWpGaD
Gefitinib—Alopecia—Betamethasone—ankylosing spondylitis	0.000393	0.00281	CcSEcCtD
Gefitinib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000393	0.00281	CcSEcCtD
Gefitinib—Angioedema—Triamcinolone—ankylosing spondylitis	0.00039	0.00279	CcSEcCtD
Gefitinib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000389	0.00278	CcSEcCtD
Gefitinib—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000389	0.00278	CcSEcCtD
Gefitinib—Haemorrhage—Prednisone—ankylosing spondylitis	0.000387	0.00277	CcSEcCtD
Gefitinib—IRAK1—MyD88-independent cascade—TLR4—ankylosing spondylitis	0.000387	0.00357	CbGpPWpGaD
Gefitinib—Malaise—Triamcinolone—ankylosing spondylitis	0.000385	0.00275	CcSEcCtD
Gefitinib—Malaise—Methylprednisolone—ankylosing spondylitis	0.000384	0.00275	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000378	0.00349	CbGpPWpGaD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TLR4—ankylosing spondylitis	0.000378	0.00348	CbGpPWpGaD
Gefitinib—Shock—Prednisolone—ankylosing spondylitis	0.000372	0.00267	CcSEcCtD
Gefitinib—Cough—Triamcinolone—ankylosing spondylitis	0.000372	0.00266	CcSEcCtD
Gefitinib—CSNK1E—Disease—ANTXR2—ankylosing spondylitis	0.000367	0.00338	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000367	0.00338	CbGpPWpGaD
Gefitinib—MAP2K5—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000364	0.00336	CbGpPWpGaD
Gefitinib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000362	0.00259	CcSEcCtD
Gefitinib—Eye disorder—Prednisone—ankylosing spondylitis	0.000362	0.00259	CcSEcCtD
Gefitinib—ERBB3—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—ankylosing spondylitis	0.000362	0.00333	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CARD9—ankylosing spondylitis	0.00036	0.00332	CbGpPWpGaD
Gefitinib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.00036	0.00258	CcSEcCtD
Gefitinib—Infestation—Methotrexate—ankylosing spondylitis	0.00036	0.00258	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00036	0.00258	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000357	0.00256	CcSEcCtD
Gefitinib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000355	0.00254	CcSEcCtD
Gefitinib—Angioedema—Betamethasone—ankylosing spondylitis	0.000354	0.00253	CcSEcCtD
Gefitinib—Angioedema—Dexamethasone—ankylosing spondylitis	0.000354	0.00253	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000351	0.00251	CcSEcCtD
Gefitinib—Angiopathy—Prednisone—ankylosing spondylitis	0.000351	0.00251	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.00035	0.00251	CcSEcCtD
Gefitinib—Malaise—Betamethasone—ankylosing spondylitis	0.000349	0.0025	CcSEcCtD
Gefitinib—Malaise—Dexamethasone—ankylosing spondylitis	0.000349	0.0025	CcSEcCtD
Gefitinib—IRAK1—Activated TLR4 signalling—TLR4—ankylosing spondylitis	0.000348	0.00321	CbGpPWpGaD
Gefitinib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000346	0.00248	CcSEcCtD
Gefitinib—Infection—Triamcinolone—ankylosing spondylitis	0.000346	0.00247	CcSEcCtD
Gefitinib—Infection—Methylprednisolone—ankylosing spondylitis	0.000345	0.00247	CcSEcCtD
Gefitinib—ERBB3—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000345	0.00318	CbGpPWpGaD
Gefitinib—Haematuria—Methotrexate—ankylosing spondylitis	0.000344	0.00246	CcSEcCtD
Gefitinib—ABCG2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000343	0.00316	CbGpPWpGaD
Gefitinib—Shock—Triamcinolone—ankylosing spondylitis	0.000342	0.00245	CcSEcCtD
Gefitinib—Alopecia—Prednisone—ankylosing spondylitis	0.000342	0.00245	CcSEcCtD
Gefitinib—Shock—Methylprednisolone—ankylosing spondylitis	0.000342	0.00245	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000341	0.00244	CcSEcCtD
Gefitinib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000341	0.00244	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—ankylosing spondylitis	0.00034	0.00243	CcSEcCtD
Gefitinib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000337	0.00241	CcSEcCtD
Gefitinib—Malnutrition—Prednisone—ankylosing spondylitis	0.000337	0.00241	CcSEcCtD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000336	0.0031	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KIR3DL1—ankylosing spondylitis	0.000333	0.00307	CbGpPWpGaD
Gefitinib—IRAK1—Toll Like Receptor 4 (TLR4) Cascade—TLR4—ankylosing spondylitis	0.000327	0.00302	CbGpPWpGaD
Gefitinib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000325	0.00233	CcSEcCtD
Gefitinib—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000324	0.00232	CcSEcCtD
Gefitinib—EGFR—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000324	0.00299	CbGpPWpGaD
Gefitinib—Pain—Prednisolone—ankylosing spondylitis	0.000324	0.00232	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—ankylosing spondylitis	0.000323	0.00232	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000323	0.00232	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000319	0.00229	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000317	0.00227	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000317	0.00292	CbGpPWpGaD
Gefitinib—Infection—Dexamethasone—ankylosing spondylitis	0.000314	0.00225	CcSEcCtD
Gefitinib—Infection—Betamethasone—ankylosing spondylitis	0.000314	0.00225	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000312	0.00288	CbGpPWpGaD
Gefitinib—Anaemia—Prednisone—ankylosing spondylitis	0.000311	0.00223	CcSEcCtD
Gefitinib—Shock—Dexamethasone—ankylosing spondylitis	0.000311	0.00222	CcSEcCtD
Gefitinib—Shock—Betamethasone—ankylosing spondylitis	0.000311	0.00222	CcSEcCtD
Gefitinib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00031	0.00222	CcSEcCtD
Gefitinib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00031	0.00222	CcSEcCtD
Gefitinib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00031	0.00222	CcSEcCtD
Gefitinib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000309	0.00221	CcSEcCtD
Gefitinib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000309	0.00221	CcSEcCtD
Gefitinib—Angioedema—Prednisone—ankylosing spondylitis	0.000308	0.0022	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000306	0.00219	CcSEcCtD
Gefitinib—Malaise—Prednisone—ankylosing spondylitis	0.000304	0.00218	CcSEcCtD
Gefitinib—IRAK4—Immune System—IL1R2—ankylosing spondylitis	0.000304	0.0028	CbGpPWpGaD
Gefitinib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000302	0.00216	CcSEcCtD
Gefitinib—Anorexia—Betamethasone—ankylosing spondylitis	0.000301	0.00215	CcSEcCtD
Gefitinib—Anorexia—Dexamethasone—ankylosing spondylitis	0.000301	0.00215	CcSEcCtD
Gefitinib—Urticaria—Prednisolone—ankylosing spondylitis	0.000301	0.00215	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.0003	0.00215	CcSEcCtD
Gefitinib—IRAK1—Innate Immune System—CARD9—ankylosing spondylitis	0.0003	0.00277	CbGpPWpGaD
Gefitinib—Fatigue—Triamcinolone—ankylosing spondylitis	0.0003	0.00215	CcSEcCtD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000299	0.00276	CbGpPWpGaD
Gefitinib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000299	0.00214	CcSEcCtD
Gefitinib—Pain—Triamcinolone—ankylosing spondylitis	0.000298	0.00213	CcSEcCtD
Gefitinib—Hypotension—Betamethasone—ankylosing spondylitis	0.000295	0.00211	CcSEcCtD
Gefitinib—Hypotension—Dexamethasone—ankylosing spondylitis	0.000295	0.00211	CcSEcCtD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TLR4—ankylosing spondylitis	0.000295	0.00272	CbGpPWpGaD
Gefitinib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000293	0.0021	CcSEcCtD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000292	0.00269	CbGpPWpGaD
Gefitinib—IRAK1—Toll-Like Receptors Cascades—TLR4—ankylosing spondylitis	0.000292	0.00269	CbGpPWpGaD
Gefitinib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000292	0.00209	CcSEcCtD
Gefitinib—IRAK4—Immune System—ERAP1—ankylosing spondylitis	0.000288	0.00265	CbGpPWpGaD
Gefitinib—Alopecia—Methotrexate—ankylosing spondylitis	0.000286	0.00205	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000285	0.00263	CbGpPWpGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000285	0.00204	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000284	0.00203	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—HLA-C—ankylosing spondylitis	0.000284	0.00262	CbGpPWpGaD
Gefitinib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000282	0.00202	CcSEcCtD
Gefitinib—EGFR—Spinal Cord Injury—IL1A—ankylosing spondylitis	0.000281	0.00259	CbGpPWpGaD
Gefitinib—ERBB3—Disease—ANTXR2—ankylosing spondylitis	0.00028	0.00258	CbGpPWpGaD
Gefitinib—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000279	0.002	CcSEcCtD
Gefitinib—MKNK1—Disease—B3GNT2—ankylosing spondylitis	0.000278	0.00256	CbGpPWpGaD
Gefitinib—IRAK4—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000277	0.00256	CbGpPWpGaD
Gefitinib—Urticaria—Triamcinolone—ankylosing spondylitis	0.000276	0.00198	CcSEcCtD
Gefitinib—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000276	0.00197	CcSEcCtD
Gefitinib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000275	0.00197	CcSEcCtD
Gefitinib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000275	0.00197	CcSEcCtD
Gefitinib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000275	0.00197	CcSEcCtD
Gefitinib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000275	0.00197	CcSEcCtD
Gefitinib—Infection—Prednisone—ankylosing spondylitis	0.000273	0.00196	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000273	0.00195	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000273	0.00195	CcSEcCtD
Gefitinib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000272	0.00195	CcSEcCtD
Gefitinib—Fatigue—Betamethasone—ankylosing spondylitis	0.000272	0.00195	CcSEcCtD
Gefitinib—Shock—Prednisone—ankylosing spondylitis	0.000271	0.00194	CcSEcCtD
Gefitinib—Pain—Betamethasone—ankylosing spondylitis	0.00027	0.00193	CcSEcCtD
Gefitinib—Pain—Dexamethasone—ankylosing spondylitis	0.00027	0.00193	CcSEcCtD
Gefitinib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00027	0.00193	CcSEcCtD
Gefitinib—IRAK4—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000269	0.00248	CbGpPWpGaD
Gefitinib—Skin disorder—Prednisone—ankylosing spondylitis	0.000267	0.00191	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.000265	0.00245	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	0.000264	0.00244	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CARD9—ankylosing spondylitis	0.000263	0.00243	CbGpPWpGaD
Gefitinib—Anorexia—Prednisone—ankylosing spondylitis	0.000262	0.00188	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—ankylosing spondylitis	0.00026	0.00186	CcSEcCtD
Gefitinib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.00026	0.00239	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000258	0.00185	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000258	0.00185	CcSEcCtD
Gefitinib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000256	0.00184	CcSEcCtD
Gefitinib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000256	0.00183	CcSEcCtD
Gefitinib—Malaise—Methotrexate—ankylosing spondylitis	0.000254	0.00182	CcSEcCtD
Gefitinib—Urticaria—Betamethasone—ankylosing spondylitis	0.000251	0.0018	CcSEcCtD
Gefitinib—Urticaria—Dexamethasone—ankylosing spondylitis	0.000251	0.0018	CcSEcCtD
Gefitinib—Asthenia—Triamcinolone—ankylosing spondylitis	0.00025	0.00179	CcSEcCtD
Gefitinib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.00025	0.00179	CcSEcCtD
Gefitinib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.00025	0.00179	CcSEcCtD
Gefitinib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00025	0.00179	CcSEcCtD
Gefitinib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00025	0.00179	CcSEcCtD
Gefitinib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000249	0.00178	CcSEcCtD
Gefitinib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000246	0.00176	CcSEcCtD
Gefitinib—Cough—Methotrexate—ankylosing spondylitis	0.000246	0.00176	CcSEcCtD
Gefitinib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000246	0.00176	CcSEcCtD
Gefitinib—MKNK1—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000243	0.00224	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1R2—ankylosing spondylitis	0.000242	0.00223	CbGpPWpGaD
Gefitinib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000239	0.00171	CcSEcCtD
Gefitinib—Rash—Prednisolone—ankylosing spondylitis	0.000239	0.00171	CcSEcCtD
Gefitinib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000238	0.00171	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000238	0.0017	CcSEcCtD
Gefitinib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000238	0.0017	CcSEcCtD
Gefitinib—Fatigue—Prednisone—ankylosing spondylitis	0.000237	0.0017	CcSEcCtD
Gefitinib—Constipation—Prednisone—ankylosing spondylitis	0.000235	0.00168	CcSEcCtD
Gefitinib—ERBB3—Immune System—ERAP1—ankylosing spondylitis	0.00023	0.00212	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—CD79A—ankylosing spondylitis	0.000229	0.00211	CbGpPWpGaD
Gefitinib—Infection—Methotrexate—ankylosing spondylitis	0.000228	0.00163	CcSEcCtD
Gefitinib—Asthenia—Betamethasone—ankylosing spondylitis	0.000227	0.00162	CcSEcCtD
Gefitinib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000227	0.00162	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—HLA-C—ankylosing spondylitis	0.000226	0.00209	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000226	0.00208	CbGpPWpGaD
Gefitinib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000226	0.00208	CbGpPWpGaD
Gefitinib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000225	0.00161	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000225	0.00161	CcSEcCtD
Gefitinib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000225	0.00161	CcSEcCtD
Gefitinib—EGFR—Spinal Cord Injury—TLR4—ankylosing spondylitis	0.000225	0.00207	CbGpPWpGaD
Gefitinib—Nausea—Prednisolone—ankylosing spondylitis	0.000225	0.00161	CcSEcCtD
Gefitinib—Pruritus—Betamethasone—ankylosing spondylitis	0.000223	0.0016	CcSEcCtD
Gefitinib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000223	0.0016	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000223	0.0016	CcSEcCtD
Gefitinib—EGFR—Immune System—KIR3DL1—ankylosing spondylitis	0.000223	0.00205	CbGpPWpGaD
Gefitinib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000221	0.00158	CcSEcCtD
Gefitinib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000221	0.00158	CcSEcCtD
Gefitinib—Rash—Triamcinolone—ankylosing spondylitis	0.000219	0.00157	CcSEcCtD
Gefitinib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000219	0.00157	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—ankylosing spondylitis	0.000219	0.00157	CcSEcCtD
Gefitinib—Rash—Methylprednisolone—ankylosing spondylitis	0.000219	0.00157	CcSEcCtD
Gefitinib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000219	0.00157	CcSEcCtD
Gefitinib—Urticaria—Prednisone—ankylosing spondylitis	0.000218	0.00156	CcSEcCtD
Gefitinib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000217	0.00156	CcSEcCtD
Gefitinib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000217	0.00156	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000217	0.002	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—B3GNT2—ankylosing spondylitis	0.000216	0.00199	CbGpPWpGaD
Gefitinib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000216	0.00155	CcSEcCtD
Gefitinib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000216	0.00155	CcSEcCtD
Gefitinib—ALB—Folate Metabolism—CRP—ankylosing spondylitis	0.000215	0.00198	CbGpPWpGaD
Gefitinib—Hypotension—Methotrexate—ankylosing spondylitis	0.000215	0.00154	CcSEcCtD
Gefitinib—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000212	0.00195	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—IL1A—ankylosing spondylitis	0.000211	0.00195	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000211	0.00194	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.00021	0.00194	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CARD9—ankylosing spondylitis	0.00021	0.00194	CbGpPWpGaD
Gefitinib—IRAK4—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.00021	0.00193	CbGpPWpGaD
Gefitinib—Nausea—Triamcinolone—ankylosing spondylitis	0.000207	0.00148	CcSEcCtD
Gefitinib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000206	0.00148	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000205	0.00147	CcSEcCtD
Gefitinib—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000203	0.00145	CcSEcCtD
Gefitinib—IRAK1—Immune System—IL1R2—ankylosing spondylitis	0.000202	0.00186	CbGpPWpGaD
Gefitinib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000201	0.00144	CcSEcCtD
Gefitinib—Vomiting—Betamethasone—ankylosing spondylitis	0.000201	0.00144	CcSEcCtD
Gefitinib—EGFR—Innate Immune System—CARD9—ankylosing spondylitis	0.000201	0.00185	CbGpPWpGaD
Gefitinib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.0002	0.00143	CcSEcCtD
Gefitinib—Rash—Betamethasone—ankylosing spondylitis	0.000199	0.00143	CcSEcCtD
Gefitinib—Rash—Dexamethasone—ankylosing spondylitis	0.000199	0.00143	CcSEcCtD
Gefitinib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000199	0.00142	CcSEcCtD
Gefitinib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000199	0.00142	CcSEcCtD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000199	0.00183	CbGpPWpGaD
Gefitinib—CHEK2—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	0.000199	0.00183	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000198	0.00142	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—ankylosing spondylitis	0.000198	0.00142	CcSEcCtD
Gefitinib—Asthenia—Prednisone—ankylosing spondylitis	0.000197	0.00141	CcSEcCtD
Gefitinib—Pain—Methotrexate—ankylosing spondylitis	0.000197	0.00141	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000195	0.0018	CbGpPWpGaD
Gefitinib—Pruritus—Prednisone—ankylosing spondylitis	0.000195	0.00139	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000194	0.00179	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000194	0.00179	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000192	0.00177	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ERAP1—ankylosing spondylitis	0.000191	0.00176	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000188	0.00174	CbGpPWpGaD
Gefitinib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000188	0.00135	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000188	0.00135	CcSEcCtD
Gefitinib—Nausea—Betamethasone—ankylosing spondylitis	0.000188	0.00134	CcSEcCtD
Gefitinib—Nausea—Dexamethasone—ankylosing spondylitis	0.000188	0.00134	CcSEcCtD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000185	0.00171	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000185	0.0017	CbGpPWpGaD
Gefitinib—IRAK1—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000184	0.0017	CbGpPWpGaD
Gefitinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000184	0.00169	CbGpPWpGaD
Gefitinib—Urticaria—Methotrexate—ankylosing spondylitis	0.000183	0.00131	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000182	0.0013	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000182	0.0013	CcSEcCtD
Gefitinib—IRAK1—Toll-like Receptor Signaling Pathway—TNF—ankylosing spondylitis	0.000178	0.00164	CbGpPWpGaD
Gefitinib—Vomiting—Prednisone—ankylosing spondylitis	0.000175	0.00125	CcSEcCtD
Gefitinib—IRAK1—Immune System—CARD9—ankylosing spondylitis	0.000175	0.00161	CbGpPWpGaD
Gefitinib—Rash—Prednisone—ankylosing spondylitis	0.000173	0.00124	CcSEcCtD
Gefitinib—Dermatitis—Prednisone—ankylosing spondylitis	0.000173	0.00124	CcSEcCtD
Gefitinib—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000171	0.00158	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.000171	0.00157	CbGpPWpGaD
Gefitinib—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000169	0.00121	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—HLA-B—ankylosing spondylitis	0.000168	0.00155	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000166	0.00153	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-C—ankylosing spondylitis	0.000165	0.00152	CbGpPWpGaD
Gefitinib—Asthenia—Methotrexate—ankylosing spondylitis	0.000165	0.00118	CcSEcCtD
Gefitinib—ERBB3—Disease—B3GNT2—ankylosing spondylitis	0.000165	0.00152	CbGpPWpGaD
Gefitinib—Nausea—Prednisone—ankylosing spondylitis	0.000163	0.00117	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—ankylosing spondylitis	0.000163	0.00116	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000157	0.00113	CcSEcCtD
Gefitinib—EGFR—Disease—ANTXR2—ankylosing spondylitis	0.000156	0.00144	CbGpPWpGaD
Gefitinib—MAP2K5—MAPK Signaling Pathway—TNF—ankylosing spondylitis	0.000149	0.00137	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—CRP—ankylosing spondylitis	0.000148	0.00137	CbGpPWpGaD
Gefitinib—Vomiting—Methotrexate—ankylosing spondylitis	0.000146	0.00105	CcSEcCtD
Gefitinib—Rash—Methotrexate—ankylosing spondylitis	0.000145	0.00104	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000145	0.00104	CcSEcCtD
Gefitinib—IRAK4—Immune System—IL1RN—ankylosing spondylitis	0.000144	0.00132	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000143	0.00131	CbGpPWpGaD
Gefitinib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000143	0.00131	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—TLR4—ankylosing spondylitis	0.000142	0.00131	CbGpPWpGaD
Gefitinib—IRAK1—Regulation of toll-like receptor signaling pathway—TNF—ankylosing spondylitis	0.000139	0.00128	CbGpPWpGaD
Gefitinib—Nausea—Methotrexate—ankylosing spondylitis	0.000137	0.000977	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000135	0.00125	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1R2—ankylosing spondylitis	0.000135	0.00124	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HLA-B—ankylosing spondylitis	0.000134	0.00123	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000134	0.00123	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-C—ankylosing spondylitis	0.000132	0.00122	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000129	0.00118	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERAP1—ankylosing spondylitis	0.000128	0.00118	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD79A—ankylosing spondylitis	0.000126	0.00116	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-C—ankylosing spondylitis	0.000126	0.00116	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000121	0.00112	CbGpPWpGaD
Gefitinib—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	0.00012	0.0011	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000119	0.0011	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—CRP—ankylosing spondylitis	0.000118	0.00109	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CARD9—ankylosing spondylitis	0.000117	0.00108	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1RN—ankylosing spondylitis	0.000115	0.00106	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—TLR4—ankylosing spondylitis	0.000113	0.00105	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HLA-A—ankylosing spondylitis	0.000113	0.00104	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000111	0.00103	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-C—ankylosing spondylitis	0.00011	0.00101	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TNF—ankylosing spondylitis	0.000106	0.000978	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000104	0.000958	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—IL1A—ankylosing spondylitis	0.000103	0.000953	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CD40LG—ankylosing spondylitis	0.000103	0.000948	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD79A—ankylosing spondylitis	0.000101	0.000927	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—CRP—ankylosing spondylitis	9.85e-05	0.000908	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-B—ankylosing spondylitis	9.78e-05	0.000901	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TNF—ankylosing spondylitis	9.73e-05	0.000897	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1RN—ankylosing spondylitis	9.54e-05	0.000879	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP3—ankylosing spondylitis	9.51e-05	0.000877	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—TLR4—ankylosing spondylitis	9.44e-05	0.000871	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—TNF—ankylosing spondylitis	9.44e-05	0.00087	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD79A—ankylosing spondylitis	9.23e-05	0.000851	CbGpPWpGaD
Gefitinib—EGFR—Disease—B3GNT2—ankylosing spondylitis	9.18e-05	0.000846	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HLA-A—ankylosing spondylitis	9.06e-05	0.000835	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HLA-A—ankylosing spondylitis	8.75e-05	0.000807	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—CRP—ankylosing spondylitis	8.64e-05	0.000797	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD79A—ankylosing spondylitis	8.37e-05	0.000772	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—TLR4—ankylosing spondylitis	8.29e-05	0.000764	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL1A—ankylosing spondylitis	8.24e-05	0.00076	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTGER4—ankylosing spondylitis	8.21e-05	0.000757	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CD40LG—ankylosing spondylitis	8.2e-05	0.000756	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TNF—ankylosing spondylitis	8e-05	0.000738	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTGER4—ankylosing spondylitis	7.92e-05	0.00073	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-B—ankylosing spondylitis	7.8e-05	0.000719	CbGpPWpGaD
Gefitinib—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	7.73e-05	0.000713	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—CD40LG—ankylosing spondylitis	7.52e-05	0.000693	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—PTGER4—ankylosing spondylitis	7.46e-05	0.000688	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HLA-B—ankylosing spondylitis	7.45e-05	0.000687	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP3—ankylosing spondylitis	7.4e-05	0.000682	CbGpPWpGaD
Gefitinib—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	7.39e-05	0.000681	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-C—ankylosing spondylitis	7.34e-05	0.000677	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HLA-A—ankylosing spondylitis	7.22e-05	0.000666	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	7.22e-05	0.000666	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—B3GNT2—ankylosing spondylitis	7.17e-05	0.000661	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-B—ankylosing spondylitis	7.16e-05	0.00066	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CRP—ankylosing spondylitis	6.89e-05	0.000635	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL1A—ankylosing spondylitis	6.86e-05	0.000633	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CD40LG—ankylosing spondylitis	6.82e-05	0.000629	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HLA-A—ankylosing spondylitis	6.67e-05	0.000615	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HLA-A—ankylosing spondylitis	6.63e-05	0.000611	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—TLR4—ankylosing spondylitis	6.61e-05	0.000609	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.59e-05	0.000607	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CRP—ankylosing spondylitis	6.59e-05	0.000607	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-B—ankylosing spondylitis	6.49e-05	0.000598	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1RN—ankylosing spondylitis	6.38e-05	0.000588	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—TLR4—ankylosing spondylitis	6.32e-05	0.000582	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HLA-A—ankylosing spondylitis	6.01e-05	0.000554	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP3—ankylosing spondylitis	5.85e-05	0.000539	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CRP—ankylosing spondylitis	5.74e-05	0.000529	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP3—ankylosing spondylitis	5.64e-05	0.00052	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD79A—ankylosing spondylitis	5.6e-05	0.000516	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—TLR4—ankylosing spondylitis	5.5e-05	0.000507	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—MMP3—ankylosing spondylitis	5.31e-05	0.00049	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—B3GNT2—ankylosing spondylitis	5.14e-05	0.000474	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—B3GNT2—ankylosing spondylitis	4.86e-05	0.000448	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP3—ankylosing spondylitis	4.69e-05	0.000433	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1A—ankylosing spondylitis	4.59e-05	0.000423	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CD40LG—ankylosing spondylitis	4.56e-05	0.000421	CbGpPWpGaD
Gefitinib—ALB—Metabolism—B3GNT2—ankylosing spondylitis	4.43e-05	0.000408	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTGER4—ankylosing spondylitis	4.41e-05	0.000406	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-B—ankylosing spondylitis	4.34e-05	0.0004	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HLA-A—ankylosing spondylitis	4.02e-05	0.000371	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	3.97e-05	0.000366	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	3.88e-05	0.000358	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CRP—ankylosing spondylitis	3.84e-05	0.000354	CbGpPWpGaD
Gefitinib—EGFR—Disease—HLA-A—ankylosing spondylitis	3.71e-05	0.000342	CbGpPWpGaD
Gefitinib—EGFR—Immune System—TLR4—ankylosing spondylitis	3.68e-05	0.000339	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	3.65e-05	0.000337	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	3.64e-05	0.000336	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	3.62e-05	0.000334	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—TNF—ankylosing spondylitis	3.38e-05	0.000311	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP3—ankylosing spondylitis	3.14e-05	0.000289	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	2.39e-05	0.00022	CbGpPWpGaD
